Philip Worboys Net Worth

The estimated Net Worth of Philip D Worboys is at least 5.93 百万$ dollars as of 9 March 2021. Philip Worboys owns over 8,829 units of Theravance Biopharma Inc stock worth over 2,783,800$ and over the last 9 years he sold TBPH stock worth over 743,063$. In addition, he makes 2,399,620$ as Senior Vice President - Research and Translational Science at Theravance Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Philip Worboys TBPH stock SEC Form 4 insiders trading

Philip has made over 4 trades of the Theravance Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 8,829 units of TBPH stock worth 176,580$ on 9 March 2021.

The largest trade he's ever made was selling 17,103 units of Theravance Biopharma Inc stock on 20 August 2020 worth over 307,854$. On average, Philip trades about 1,045 units every 26 days since 2016. As of 9 March 2021 he still owns at least 343,679 units of Theravance Biopharma Inc stock.

You can see the complete history of Philip Worboys stock trades at the bottom of the page.

Philip Worboys biography

Dr. Philip D. Worboys Ph.D. serves as Senior Vice President - Research and Translational Science of the Company., serves as Senior Vice President, Translational Science of the Company. Dr. Worboys has served as our Senior Vice President, Translational Science since March 2016, where is he responsible for leading the progression of drug candidates from the discovery stage into human clinical studies, including clinical pharmacology and biomarker development as well as project management. Previously, Dr. Worboys was Vice President, Drug Metabolism and Pharmacokinetics (DMPK) since he joined Theravance Biopharma in October 2014 from Innoviva, where he held the position of Vice President, DMPK since November 2008. Prior to joining Innoviva, he served as Senior Director, DMPK at Roche Bioscience, Inc. since 2005. Dr. Worboys was an Associate Director, DMPK at Pharmacia Corporation from 2001 until its acquisition by Pfizer, Inc. and was Senior Director, DMPK at Pfizer, Inc. from 2003 to 2005. He spent the first part of his career in DMPK, at Merck Sharp & Dohme in Harlow, United Kingdom, and worked in various capacities at Aventis, Unilever and GlaxoSmithKline prior to that. Dr. Worboys obtained his Ph.D. degree in Pharmaceutics from Manchester University, United Kingdom. He holds a B.Sc. degree in Biochemistry from Imperial College of Science, Technology & Medicine at the University of London.

What is the salary of Philip Worboys?

As the Senior Vice President - Research and Translational Science of Theravance Biopharma Inc, the total compensation of Philip Worboys at Theravance Biopharma Inc is 2,399,620$. There are 5 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of 5,932,410$.

How old is Philip Worboys?

Philip Worboys is 50, he's been the Senior Vice President - Research and Translational Science of Theravance Biopharma Inc since 2019. There are 20 older and 5 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.

What's Philip Worboys's mailing address?

Philip's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Theravance Biopharma Inc

Over the last 11 years, insiders at Theravance Biopharma Inc have traded over 11,619,559$ worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth 29,986,832,769,275$ . The most active insiders traders include Plc Gsk、Inc. Innoviva,、Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of 448,635$. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth 7,798,440$.

What does Theravance Biopharma Inc do?

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Complete history of Philip Worboys stock trades at Theravance Biopharma Inc

Theravance Biopharma Inc executives and stock owners

Theravance Biopharma Inc executives and other stock owners filed with the SEC include:

• Rick Winningham,
  Chairman of the Board, Chief Executive Officer
• Andrew Hindman,
  Chief Financial Officer, Senior Vice President
• Bradford Shafer,
  Executive Vice President, General Counsel, Secretary
• Brett Haumann,
  Senior Vice President, Clinical Development and Chief Medical Officer
• Frank Pasqualone,
  Senior Vice President and Chief Commercial Operations Officer
• Philip Worboys,
  Senior Vice President - Research and Translational Science
• Rick E. Winningham M.B.A.,
  Chairman & CEO
• Andrew Asa Hindman,
  Sr. VP & CFO
• Bradford J. Shafer,
  Exec. VP, Gen. Counsel & Sec.
• Andrew Asa Hindman M.B.A,
  Sr. VP & CFO
• Rhonda F. Farnum,
  Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs
• William Young,
  Lead Independent Director
• Burton Malkiel,
  Independent Director
• Donal O'Connor,
  Independent Director
• Dean Mitchell,
  Independent Director
• Susan Molineaux,
  Independent Director
• Eran Broshy,
  Independent Director
• Laurie Alsup,
  Independent Director
• George Whitesides,
  Independent Director
• Robert Gunderson,
  Director
• Deepika Pakianathan,
  Independent Director
• Vijay Sabesan,
  Senior Vice President - Technical Operations
• Kenneth Pitzer,
  Senior Vice President - Product Strategy and Commercial Planning
• Ann Brady,
  President - Theravance Biopharma Ireland Limited
• Dr. Ann B. Brady Ph.D.,
  Pres of Theravance Biopharma Ireland Limited
• Dr. Richard A. Graham Ph.D.,
  Sr. VP of Devel.
• Daniel Long,
  Head of Medicinal Chemistry
• Dr. Kenneth R. Pitzer,
  Sr. VP of Product Strategy & Commercial Planning
• Dr. Phillip D. Worboys,
  Sr. VP of Research & Translational Science
• Dennis O. Driver,
  Sr. VP of HR, Organizational and Leadership Devel.
• Gail B. Cohen,
  VP of Corp. Communications & Investor Relations
• Jeremy T Grant,
  
• Renee D Gala,
  VP-Finance
• Peter S Ringrose,
  Director
• Junning Lee,
  Sr. VP, Technical Operations
• Sharathchandra S Hegde,
  SVP, Research
• Henrietta Fore,
  Director
• Shehnaaz Suliman,
  SVP, Corp Dev & Strategy
• Jeffrey David Jonker,
  Senior VP, Corp. & Bus. Dev.
• Michael G Atieh,
  Director
• Leonard M Blum,
  Sr VP, Chief Comm. Officer
• Inc. Innoviva,,
  10% owner
• Mathai Mammen,
  SVP, Research & Early Clin Dev
• Rhonda Farnum,
  SVP, COMM & MEDICAL AFFAIRS
• Richard A Graham,
  SVP, RESEARCH & DEVELOPMENT
• Plc Gsk,
  
• Aziz Sawaf,
  SVP & CHIEF FINANCIAL OFFICER
• Brett A. Grimaud,
  SVP, GEN COUNSEL AND SECRETARY
• Susannah Gray,
  
• Aine Miller,
  SVP, DEV & HEAD OF IRE OFFICE
• Eli Samaha,
  10% owner